Dare Bioscience Inc
$ 1.72
1.78%
11 Feb - close price
- Market Cap 22,780,400 USD
- Current Price $ 1.72
- High / Low $ 1.77 / 1.69
- Stock P/E N/A
- Book Value 0.20
- EPS -1.83
- Next Earning Report 2026-03-30
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.45 %
- ROE -25.43 %
- 52 Week High 3.31
- 52 Week Low 1.61
About
Dare Bioscience, Inc. is a clinical-stage biopharmaceutical company based in San Diego, California, committed to advancing women's health through a portfolio of innovative therapeutic solutions. With a focused pipeline addressing significant unmet medical needs, the company aims to improve patient outcomes across various facets of women's health. By prioritizing unique challenges faced by women, Dare Bioscience is strategically positioned to become a leader in the transformation of healthcare for women, leveraging its expertise to enhance life quality and drive impactful commercialization of its products.
Analyst Target Price
$10.75
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-13 | 2025-08-14 | 2025-05-05 | 2025-03-26 | 2024-11-07 | 2024-08-08 | 2024-05-14 | 2024-03-28 | 2023-11-09 | 2023-08-10 | 2023-05-11 | 2023-03-30 |
| Reported EPS | -0.28 | -0.45 | -0.5 | -0.65 | -0.55 | -0.88 | -0.07 | -0.06 | -0.09 | -0.1 | -0.09 | -0.19 |
| Estimated EPS | 0.02 | 0.03 | -0.58 | -0.6333 | -0.73 | 0.02 | -0.06 | -0.1 | -0.1 | -0.1 | -0.1 | -0.14 |
| Surprise | -0.3 | -0.48 | 0.08 | -0.0167 | 0.18 | -0.9 | -0.01 | 0.04 | 0.01 | 0 | 0.01 | -0.05 |
| Surprise Percentage | -1500% | -1600% | 13.7931% | -2.637% | 24.6575% | -4500% | -16.6667% | 40% | 10% | 0% | 10% | -35.7143% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-03-30 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | -0.31 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: DARE
2026-02-11 13:57:31
Dare Bioscience (DARE) has launched telehealth services for its DARE to PLAY Sildenafil Cream, making it accessible across all 50 continental states to enhance women's sexual health solutions. Despite this innovative product offering, the company faces significant financial challenges, highlighted by a distressing Altman Z-Score and negative earnings growth. The stock's current valuation suggests potential undervaluation relative to book value, with an analyst target price indicating possible upside if financial hurdles are overcome.
2026-02-11 12:57:31
Daré Bioscience, Inc. announced the availability of telehealth consultations for DARE to PLAY™ Sildenafil Cream, a topical arousal cream for women. This allows women nationwide to begin the process of obtaining a prescription for the clinically studied product through the DARE Health Hub, powered by Medvantx Pharmacy. The company aims to address the lack of FDA-approved therapeutics for female genital arousal challenges and plans for future market introduction and FDA approval pursuits.
2026-02-11 12:57:31
Daré Bioscience has launched nationwide telehealth access for its DARE to PLAY™ Sildenafil Cream, a non-hormonal topical arousal cream for women. This product, supported by clinical studies showing increased genital blood flow and improved arousal, is a significant stride in addressing unmet needs in women's sexual health. Through the DARE Health Hub, women can now undergo telehealth consultations to obtain a prescription, with pre-fulfillment benefits including discounts and priority access once pharmacy dispensing begins.
2026-02-04 11:28:59
Analysts are optimistic about Daré Bioscience, Inc. (NASDAQ:DARE), predicting the company will reach breakeven and become profitable by 2027, generating US$21m in profits. This forecast requires an average annual growth rate of 59%, indicating high analyst confidence. The company's lack of debt is a notable positive, reducing investment risk for this loss-making pharma.
2026-02-04 10:30:15
Analysts are optimistic about Daré Bioscience, Inc. (NASDAQ:DARE) reaching profitability, with a consensus forecasting breakeven in 2026 and positive profits of US$21 million in 2027. This projection relies on an aggressive average annual growth rate of 59%. The company's debt-free balance sheet is noted as a significant positive, reducing investment risk for this loss-making pharma company.
2026-01-29 23:45:03
Dare Bioscience (NASDAQ:DARE) announced the initial closing of a Regulation A offering, issuing Series A Convertible Preferred Stock and warrants. The offering is part of a plan to raise capital, with each unit priced at $5.00, comprising one preferred share and two warrants. This financing comes as the microcap biotech is burning cash, though analysts have set price targets between $8 and $12 per share, and InvestingPro assesses its financial health as "FAIR."
